By almost any measure, the US has the most complex and most expensive healthcare system in the developed world. Americans pay, on average, rou branded medicines than patients in other developed nations. The reasons are often attributed to pharmaceutical companies themselves. Certain political and consumer groups frequently accuse Big Pharma of e exorbitant pricing. While there is some merit to this criticism, it tells only a part of the story.

To understand why drug prices are so high in the US, one must look beyond the pharmaceutical industry itself and into the complex network of interm structural quirks that define the US healthcare system. The economics of pharmaceuticals Drug development is a lengthy, risky and expensive endeavour. Pharmaceutical and biotechnology companies begin by identifying a disease-relevant protein or strand of ribonucleic acid (RNA).

Scientists then screen molecules to find one capable of influencing that target. Promising candidates ente before entering the long clinical development process in humans. From discovery to approval, the journey typically takes ten to fifteen years. Even then, success is far from guaranteed. For every Pfizer or Eli Lilly, there exists a long tail of failed drug programmes and biotech startups. Additionally, the make-up of the healthcare system responsible for the current state of play.

Between 2021 and 2024, the probability that a drug entering Phase 1 clinical trials would ultimately receive approval from the US Food and Drug Adm between 7% to 12%. Put plainly, drug development requires a more-than-decade-long commitment with around a one-in-ten chance of success. In any unfavourable wager. Patent law compounds the challenge.

Pharmaceutical companies usually file for protection (patents) at the pre-clinical stage, starting a twenty-year p development alone consumes roughly half of that period, the window of commercial exclusivity is often less than a decade. Once a patent expires, ge competition enters the market quickly, and the drug’s revenue typically collapses. The experience of AbbVie’s blockbuster immunology drug Humira illustrates the point (see Figure 2).

At its peak in 2022, Humira was the world’s bestUS$21bn in annual revenue. When its patent expired in January 2023, biosimilar alternatives flooded the market, and sales have fallen by c. 86% sinc

Given this dynamic, pharma companies are naturally incentivised to extract maximum economic value from an approved drug while exclusivity lasts. realised, the capital required to fund new life-saving treatments evaporates.

So, while individuals can criticise the high gross margins earned by pharma companies, they often forget the sunk costs that preceded those margins The anatomy of a drug’s price tag Branded drugs are expensive because they are costly to make, but this does not fully explain the pricing mismatch between the US and other develope difference lies in how prices are negotiated.

The US is that rare developed nation without a central authority to negotiate or set drug prices for its popu Elsewhere, developed nation governments wield significant buying power. In the UK, for example, the National Institute for Health and Care Excellence medicine justifies its asking price, after which the National Health Service (NHS) negotiates the final reimbursement level. Similar national framework Australia and France.

In Australia, prices are negotiated nationally and tied to a central formulary, while in France, they are set through a process grou In each of these markets, there is ultimately one negotiated price. The US operates very differently. Pharmaceutical companies do set a uniform list price, but that figure is rarely what anyone actually pays.

Instead, the list price serves as a starting po through a chain of wholesalers, pharmacy benefit managers (PBMs), Medicare, Medicaid, private insurers, and pharmacies. Each participant in that ch discounts, rebates, and fees.

Because these downstream costs are pegged to the list price, pharma companies are incentivised to set the list price as high as possible. The high list inflates what vulnerable patients pay while keeping the underlying additive transactions hidden from view. The intermediaries who ate the system The fragmented nature of the US healthcare system has given rise to a type of intermediary that exists nowhere else in the developed world – PBMs.

PBMs originally emerged as administrative intermediaries – processing claims and designing formularies to help employers and insurers navigate a f however, PBMs have grown into an industry of their own, becoming powerful gatekeepers in the pharmaceutical supply chain. Today, the three largest c. 6.6bn prescriptions dispensed annually in the US.

Their core function is negotiating rebates from drug manufacturers in exchange for favourable placement on formularies – the list of medicines insur competition should lower drug prices. In practice, it has done the opposite. To maximise rebate revenue, PBMs have been found to favour a higher-priced drug offering a larger rebate over a cheaper alternative.

In this structure insurers receive their rebate payments, PBMs collect their fee, and the pharmaceutical manufacturers retain their premium price. Everyone in the chain The state of the nation

however, moved to replace theIDs system with single national buyer of the kind seenaffect in the UKfeatures or Australia. to process neither data such has as browsing behaviour or unique on this site. Notaconsenting or withdrawing consent, may adversely certain and functions.

The most significant reform came under the Biden administration through the Inflation Reduction Act (IRA). The legislation overturned the long-standi which had explicitly prohibited Medicare from negotiating drug prices directly with manufacturers. The reforms introduced several important changes Medicare can now negotiate prices on certain high-cost medicines. Annual out-of-pocket prescription costs for beneficiaries are capped at US$2,000.

Pharmaceutical companies are now required to pay rebates to Medicare if drug prices rise faster than inflation.

Subsequent reforms under the Trump administration have pursued a complementary approach. To close the gap between US and global prices, it has  ANCHOR price benchmarking — linking the maximum fair price (MFP) of certain Medicare drugs to the average prices paid by other G7 nations. In doing so, the the collective negotiating leverage of the global market. At the same time, policymakers are targeting the intermediaries themselves.

New federal transparency mandates require PBMs to disclose payments Legislative proposals are also underway to separate PBM compensation from drug list prices, removing the incentive for intermediaries to prefer bran expensive) over cheaper generics. Where the system is heading These reforms suggest that the “Wild West” era of US drug pricing may be coming to an end.

The US is gradually moving toward a value-based pricin medicines is more closely tied to their clinical benefit rather than what the market will tolerate. Significant challenges remain. Expanding reforms beyond Medicare to all private insurance markets would represent a major structural shift. Still, the continued to warn that aggressive pricing controls risk creating an “innovation wasteland,” and legal challenges are likely to persist.

Nevertheless, it w momentum has shifted, and the public’s appetite for the status quo has evaporated. More progress on drug pricing reform has been made over the pa preceding two decades. For investors and policymakers, the key takeaway is that the future of US pharmaceutical pricing will likely be shaped less by the drug manufacturers complex system of intermediaries that grew around them.